Redeye: Alelion - Booked 2023 orders to generate 180% sales growth
Redeye updates its estimates following Alelion’s Q3 2022 report, where the main events were the orders from Terberg (September) and Kalmar (October) corresponding to SEK370m. With a 2023 order backlog of SEK230m and increasing order intake from key customers, we consider Alelion to be well-positioned to deliver ramping sales growth in the coming years.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/